本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 证券代码：603182 证券简称：嘉华股份 公告编号：2025-031 山东嘉华生物科技股份有限公司 2025年第一次临时股东大会决议公告 (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由董事长李广庆先生主持，采用现场投票和网络投票相结合的方式 表决，会议的召集、召开程序及出席会议人员的资格均符合《公司法》和《公司 章程》的有关规定。 (五)公司董事、监事和董事会秘书的出席情况 二、 议案审议情况 (一)非累积投票议案 (一)股东大会召开的时间：2025 年 10 月 29 日 (二)股东大会召开的地点：公司会议室（山东省聊城市莘县鸿图街 19 号） (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 65 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 58,275,107 | ...

山东儒玥（青岛）律师事务所 关于山东嘉华生物科技股份有限公司 2025年第一次临时股东大会的 法律意见书 山东儒玥（青岛）律师事务所 关于山东嘉华生物科技股份有限公司 2025年第一次临时股东大会的 法律意见书 法律意见书 二〇二五年十月 致：山东嘉华生物科技股份有限公司 山东儒玥（青岛）律师事务所（以下简称"本所"）接受山东嘉华生物科技 股份有限公司（以下简称"公司"）委托，就公司2025年第一次临时股东大会 （以下简称"本次股东大会"）的相关事宜出具《山东儒玥（青岛）律师事务所 关于山东嘉华生物科技股份有限公司2025年第一次临时股东大会的法律意见书》 （以下简称"本《法律意见书》"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）《中 华人民共和国证券法》（以下简称"《证券法》"）《上市公司股东会规则 （2025修订）》（以下简称"《股东会规则》"）《上海证券交易所上市公司自 律监管指引第1号—规范运作（2025年5月修订）》和《山东嘉华生物科技股份有 限公司章程》（以下简称"《公司章程》"）等规定，就本次股东大会的召集和 召开程序、召集人和出席人员的资格、表决程序以及表决结果发表法律 ...

Core Viewpoint - Jia Hua Co., Ltd. (603182.SH) reported a decline in total operating revenue for the first three quarters of 2025, while net profit attributable to shareholders increased year-on-year [1] Financial Performance - Total operating revenue for the first three quarters reached 1.027 billion yuan, a year-on-year decrease of 7.19% [1] - Net profit attributable to shareholders was 82.173 million yuan, reflecting a year-on-year growth of 7.46% [1] - Basic earnings per share stood at 0.5 yuan [1]

Core Insights - The company reported a revenue of 346 million yuan in Q3 2025, representing a year-on-year growth of 6.46% [2] - The net profit attributable to shareholders for Q3 2025 was 19.88 million yuan, showing a year-on-year increase of 6.44% [2] - For the first three quarters of 2025, the company achieved a total revenue of 1.027 billion yuan, which is a year-on-year decline of 7.19% [2] - The net profit attributable to shareholders for the first three quarters was 82.17 million yuan, reflecting a year-on-year growth of 7.46% [2]

Group 1 - The core viewpoint of the article highlights the financial performance of Jia Hua Co., Ltd. for the third quarter of 2025, indicating a decline in revenue but an increase in net profit and earnings per share [1] Group 2 - For the first three quarters of 2025, Jia Hua Co., Ltd. reported revenue of approximately 1.027 billion yuan, representing a year-on-year decrease of 7.19% [1] - The net profit attributable to shareholders was approximately 82.17 million yuan, showing a year-on-year increase of 7.46% [1] - The basic earnings per share increased to 0.5 yuan, reflecting an 8.7% year-on-year growth [1] Group 3 - As of the report date, the market capitalization of Jia Hua Co., Ltd. was 2.5 billion yuan [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上海证券交易所上市公司自律监管指引第 3 号行业信息披露：第十四 号——食品制造》的相关要求，山东嘉华生物科技股份有限公司（以下简称"公 司"）现将 2025 年前三季度主要经营数据公告如下： | 项目 | 金额 | 比例（%） | | --- | --- | --- | | 大豆蛋白 | 60,916.36 | 59.48 | | 大豆油 | 22,652.71 | 22.12 | | 大豆膳食纤维 | 6,348.44 | 6.20 | | 低温食用豆粕 | 2,987.91 | 2.92 | | 蒸汽 | 3,941.48 | 3.85 | | 电力 | 2,495.07 | 2.43 | | 副产品 | 3,071.29 | 3.00 | | 合计 | 102,413.26 | 100.00 | 一、按产品类别分类的销售情况 单位：万元 证券代码：603182 证券简称：嘉华股份 公告编号：2025-030 山东嘉华生物科技股份有限公司 2025 年前三季度主要经营 ...

Financial Performance - The company's operating revenue for Q3 2025 was CNY 345,616,480.67, representing a year-on-year increase of 6.46%[4] - The total profit for the period was CNY 25,684,437.47, up 4.74% compared to the same period last year[4] - The net profit attributable to shareholders was CNY 19,881,809.16, reflecting a 6.44% increase year-on-year[4] - The net profit after deducting non-recurring gains and losses was CNY 19,878,154.22, which is a 16.05% increase compared to the same period last year[4] - Total operating revenue for the first three quarters of 2025 was CNY 1,026,724,570.23, a decrease of 7.2% compared to CNY 1,106,258,704.92 in the same period of 2024[19] - Total profit for the first three quarters of 2025 was CNY 107,865,840.67, compared to CNY 100,315,740.31 in 2024, indicating an increase of 7.6%[20] - Net profit for the first three quarters of 2025 was CNY 82,173,048.86, an increase of 7.3% from CNY 76,465,591.07 in 2024[21] Earnings and Shareholder Information - The basic earnings per share for the period was CNY 0.12, consistent with the previous year[5] - The diluted earnings per share also stood at CNY 0.12, unchanged from the previous year[5] - Basic earnings per share for the first three quarters of 2025 was CNY 0.50, compared to CNY 0.46 in the same period of 2024, representing an increase of 8.7%[21] Cash Flow and Operating Activities - The cash flow from operating activities for the year-to-date was CNY 94,430,151.60, showing a decrease of 34.51% year-on-year[4] - Net cash flow from operating activities for the first three quarters of 2025 was CNY 94,430,151.60, a decrease of 34.5% from CNY 144,192,554.70 in 2024[22] - The company reported a net cash outflow from investing activities of CNY -35,361,440.12 for the first three quarters of 2025, compared to CNY -185,932,102.85 in 2024[23] - The company experienced a net cash outflow from financing activities of CNY -88,584,820.44 in the first three quarters of 2025, compared to CNY -61,326,059.08 in 2024[23] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,307,504,783.66, down 8.70% from the end of the previous year[5] - The company's current assets decreased to RMB 462,411,222.05 from RMB 540,749,473.77, representing a reduction of about 14.5%[14] - Cash and cash equivalents decreased to RMB 119,489,846.73 from RMB 147,277,481.35, indicating a decline of approximately 18.9%[14] - Accounts receivable increased significantly to RMB 106,252,737.65 from RMB 78,601,924.76, marking an increase of about 35.2%[14] - Inventory decreased to RMB 156,914,431.92 from RMB 225,498,541.32, a reduction of approximately 30.4%[14] - Total liabilities decreased to RMB 212,525,283.65 from RMB 356,758,966.27, reflecting a decline of about 40.4%[16] - The total non-current assets decreased to RMB 845,093,561.61 from RMB 891,327,337.31, a decline of approximately 5.2%[15] Equity and Shareholder Structure - The equity attributable to shareholders was CNY 1,094,979,500.01, an increase of 1.83% compared to the end of the previous year[5] - The company's equity attributable to shareholders increased to RMB 1,094,979,500.01 from RMB 1,075,317,844.81, showing a growth of approximately 1.8%[16] - The company has not reported any significant changes in its shareholder structure or any new strategies during the reporting period[13] Research and Development - Research and development expenses for the first three quarters of 2025 were CNY 7,351,472.44, a decrease of 10.3% from CNY 8,192,969.79 in 2024[19] Prepayments - The company reported a significant increase in prepayments, rising to RMB 8,764,337.56 from RMB 1,118,063.63, an increase of about 684.5%[14]

山东嘉华生物科技股份有限公司 2025年第一次临时股东大会 山 东 嘉 华 生 物 科 技 股 份 有 限 公 司 2025 年第一次临时股东大会 会 议 资 料 $$\Xi{\cal O}\,{\underline{{{-\,}}}}\,\Xi{\cal H}\,\rlap{/}\Xi+{\cal H}$$ 二、出席会议的股东及股东代理人须在会议召开前半小时到会议现场办理 签到手续，并按规定出示身份证原件及股东证券账户卡或其他能够证明其股东身 份的有效证件、法人股东营业执照(复印件并加盖公章)、授权委托书等，上述登 记材料均需提供复印件一份，经验证后方可出席现场会议。会议开始后，由会议 主持人宣布现场出席会议的股东人数及其所持有表决权的股份总数，在此之后进 场股东无权参与现场投票表决。 山东嘉华生物科技股份有限公司 2025年第一次临时股东大会 目 录 | 2025 年第一次临时股东大会会议须知 1 | | --- | | 2025 年第一次临时股东大会会议议程 3 | | 2025 年第一次临时股东大会会议议案 4 | | 议案一、关于取消监事会并修订《公司章程》的议案 5 | | 议案二、关于修订《股东 ...

Core Insights - The agricultural processing sector saw a 0.8% increase on October 15, with Zunming Co. leading the gains [1] - The Shanghai Composite Index closed at 3912.21, up 1.22%, while the Shenzhen Component Index closed at 13118.75, up 1.73% [1] Agricultural Processing Sector Performance - Zunming Co. (003030) closed at 19.54, up 5.51% with a trading volume of 38,800 lots and a transaction value of 74.5 million yuan [1] - Guangnong Sugar Industry (000911) closed at 7.68, up 4.77% with a trading volume of 236,200 lots and a transaction value of 183 million yuan [1] - Yongshuntai (001338) closed at 11.98, up 4.63% with a trading volume of 269,200 lots and a transaction value of 324 million yuan [1] - Other notable performers include Guotou Zhonglu (600962) at 21.99 (+3.82%), Baolingbao (002286) at 9.97 (+3.10%), and Suobao Protein (603231) at 19.05 (+1.65%) [1] Capital Flow Analysis - The agricultural processing sector experienced a net inflow of 23.09 million yuan from main funds, while retail funds saw a net outflow of 23.04 million yuan [2] - Main funds showed significant inflows in Yongshuntai (6.01 million yuan) and Guangnong Sugar Industry (2.88 million yuan) [3] - Retail investors had notable outflows in Yongshuntai (-40.62 million yuan) and Guangnong Sugar Industry (-24.46 million yuan) [3]

山东嘉华生物科技股份有限公司 董事和高级管理人员所持本公司股份 及其变动管理制度 （2025 年 10 月修订） 第一章 总 则 第一条 为加强对山东嘉华生物科技股份有限公司（以下简称"公司" 或"本公司"）董事、高级管理人员所持本公司股份及其变动的管理，根 据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司股东减持股份 管理暂行办法》《上市公司董事和高级管理人员所持本公司股份及其变动 管理规则》《上海证券交易所上市公司自律监管指引第 8 号——股份变动 管理》等法律、法规和规范性文件以及《山东嘉华生物科技股份有限公司 章程》（以下简称"《公司章程》"）的规定，制定本制度。 第二条 公司董事和高级管理人员应当遵守《公司法》《证券法》和有 关法律、行政法规，中国证监会规章、规范性文件以及上海证券交易所规 则中关于股份变动的限制性规定。 公司董事和高级管理人员对持有股份比例、持有期限、变动方式、变动数 量、变动价格等作出承诺的，应当严格履行所作出的承诺。 第三条 公司董事和高级管理人员所持本公司股份，是指登记在其名下 和利用他人账户持有的所有本公 ...